Ozempic & Chronic Kidney Disease: Clinical Evidence

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists like Ozempic have demonstrated potential renal protective effects in chronic kidney disease (CKD) patients, primarily through improved glucose control and blood pressure reduction. Clinical trials show a 24% reduction in CKD progression risk in patients with type 2 diabetes and existing kidney disease.

For patients exploring GLP-1 options to support kidney health alongside diabetes management, understanding the evidence and how personal factors influence outcomes is essential. PlexusDx supports precision-informed conversations by combining clinical guidance with optional genetic insights into peptide-pathway predispositions.

The Mechanism: How GLP-1 Agonists May Protect Kidney Function

GLP-1 receptor agonists work through multiple pathways that may benefit kidney health. They improve insulin secretion, reduce blood glucose, and lower blood pressure—three critical factors in slowing CKD progression. Additionally, these medications reduce inflammation and improve endothelial function in kidney vasculature.

Research suggests GLP-1 agonists may reduce albuminuria (protein in urine) and stabilize the glomerular filtration rate (GFR), key markers of kidney function. The cardiovascular benefits—reduced heart attack and stroke risk—indirectly protect kidneys by improving overall vascular health and reducing hypoxia-driven kidney damage.

Clinical Evidence: Key Outcomes in CKD and Kidney Disease Studies

Multiple large-scale trials have evaluated GLP-1 agonist effects on kidney outcomes in CKD populations. Data from LEADER, SUSTAIN-6, and DECLARE-TIMI 58 trials show consistent renal protection, while newer evidence from FLOW trial examines tirzepatide (a dual GIP/GLP-1 agonist) specifically in non-diabetic CKD.

Study/Trial	Population	Key Kidney Outcome	Clinical Significance
LEADER (liraglutide)	Type 2 diabetes with CKD	22% reduction in new/worsening nephropathy	First evidence of GLP-1 renal benefit
SUSTAIN-6 (semaglutide)	Type 2 diabetes, high CV risk	36% reduction in sustained albuminuria doubling	Strong proteinuria reduction
DECLARE-TIMI 58 (dapagliflozin)	Type 2 diabetes, no prior MI/stroke	47% reduction in CKD progression events	Cardiovascular + renal synergy
FLOW Trial (tirzepatide)	Type 2 diabetes, eGFR 25–90	35% risk reduction in kidney disease worsening	Dual-pathway approach shows promise

Who Benefits Most: Patient Factors and Eligibility Considerations

GLP-1 agonists are most beneficial for patients with type 2 diabetes and existing CKD or albuminuria, particularly those with baseline eGFR above 25 mL/min/1.73m². Benefits extend to overweight or obese patients where weight loss further reduces kidney stress and blood pressure. Patients with concurrent hypertension or cardiovascular disease are candidates for particularly strong renal protection.

Conversely, patients with advanced CKD (Stage 5, eGFR <15), on dialysis, or with type 1 diabetes should discuss GLP-1 therapy carefully with nephrology providers. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe gastrointestinal disease that limits tolerability.

Safety Profile and Monitoring Recommendations for CKD Patients

GLP-1 agonists are generally well-tolerated in CKD, but kidney-specific monitoring is essential. Providers typically check serum creatinine, eGFR, and urine albumin-to-creatinine ratio (UACR) at baseline and regularly during treatment. Dehydration, acute kidney injury risk, and gastrointestinal side effects (nausea, constipation) require careful management, especially in older patients or those with reduced kidney function.

Dose adjustments may be necessary in advanced CKD (eGFR <30). Patients should maintain adequate hydration, avoid NSAIDs when possible, and report symptoms like reduced urine output, severe nausea, or unexplained fatigue immediately. A collaborative approach between endocrinologists, nephrologists, and primary care providers optimizes safety and kidney outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that GLP-1 response varies by individual genetic predispositions in peptide-pathway signaling. Our Precision Peptide Genetic Test may help provide context by revealing variations in key receptors like GLP1R and GIPR, which influence medication efficacy and side-effect tolerance. This information should be interpreted with a qualified healthcare provider to inform personalized dosing and formulation selection.

The genetic test examines predispositions in GLP-1 receptor variants and glucose-metabolism genes (FTO, MC4R) relevant to kidney-health outcomes. These predispositions do not guarantee exact medication response or kidney-function improvement, but can support a more nuanced conversation about which GLP-1 approach—compounded semaglutide, tirzepatide, or alternative formulations—may align with your individual physiology.

For CKD patients considering GLP-1 therapy, combining genetic insights with regular biomarker monitoring (eGFR, UACR, blood pressure) allows providers to optimize treatment over time. PlexusDx compounded GLP-1 options, sourced from licensed 503A pharmacies, provide flexible dosing and formulations that can be adjusted based on individual tolerance and kidney-function trajectory.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.